The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment.

The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment.

<h4>Background</h4>Renal impairment is a common feature in multiple myeloma and is considered a poor prognostic factor.<h4>Aim</h4>To determine the impact of novel drugs (i.e. bortezomib, lenalidomide and thalidomide) in the treatment of myeloma patients with renal impairment...

Full description

Bibliographic Details
Main Authors: Katarina Uttervall, Adil D Duru, Johan Lund, Johan Liwing, Gösta Gahrton, Erik Holmberg, Johan Aschan, Evren Alici, Hareth Nahi
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/25003848/pdf/?tool=EBI

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/25003848/pdf/?tool=EBI

Similar Items